Delivery Order SPE2DB24D1205-SPE2DB25FCZBJ
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Dupixent 300 mg/2 mL pens with a ceiling value of $3,418.92. This non-competitive, firm fixed-price delivery order is scheduled for completion by August 12, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe eczema, asthma, and other...
- The Defense Logistics Agency awarded a $68,986.58 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen auto-injectors on July 30, 2025, with an ultimate completion date of July 31, 2025. This non-competitive delivery order represents a firm fixed price transaction under an existing Indefinite Delivery Contract vehicle. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to...
- The Defense Logistics Agency awarded a $26,543.31 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dupixent 300 mg/2 mL pens (2 mL units). This firm fixed-price contract, which carries no set-aside designation, is classified as a delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The place of performance is listed as Conshohocken, Pennsylvania, the company's corporate headquarters, with an ultimate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Dupixent 300 mg/2 mL pens totaling $20,114.60 with completion scheduled for July 22, 2025. This competitive, non-set-aside contract represents a firm fixed price delivery order under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Dupixent 300 mg/2 ml pens with a ceiling value of $43,275.69. This firm fixed-price, non-set-aside contract is scheduled for completion by August 13, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat conditions including atopic dermatitis, eczema, asthma, and...
- The Defense Logistics Agency awarded a $3,480.12 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pens on August 12, 2025, with an ultimate completion date of August 13, 2025. This non-competitive delivery order represents a single pharmaceutical product shipment to support federal medical procurement needs. The awardee, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for military and veteran...
- The Defense Logistics Agency awarded a $21,060.94 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Dupixent 300 mg/2 mL pens. This non-competitive, firm fixed price delivery order is expected to be completed by July 28, 2025, and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication commonly used to treat moderate-to-severe atopic dermatitis, eosinophilic esophagitis, and moderate-to-severe...
- On August 15, 2025, the Defense Logistics Agency's Medical Supply Chain awarded a delivery order valued at $97,415.40 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens (2 mL quantity). This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 18, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. The contract contains no set-aside designation, reflecting open competition among...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Dupixent 300 mg/2 mL pen injections with a ceiling value of $53,159.79. This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 18, 2025, and performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic immunosuppressant medication commonly used to treat...
- The Defense Logistics Agency awarded a delivery order valued at $7,827.15 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on July 28, 2025, with an ultimate completion date of July 29, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe eczema, asthma, and other inflammatory...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FCZBJDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Dupixent 300 mg/2 mL pens with a ceiling value of $46,237.16. This firm fixed-price delivery order, with an ultimate completion date of July 31, 2025, represents a competitively awarded, non-set-aside procurement executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The place of performance is located at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic immunosuppressant used to treat moderate-to-severe eczema, asthma, and other allergic conditions, making it a critical pharmaceutical commodity for military and veteran healthcare systems. This delivery order exemplifies AmerisourceBergen's role as a primary vendor for the Defense Health Agency's pharmaceutical supply chain, delivering specialized medications across multiple therapeutic domains to support military medicine worldwide. The award reinforces the company's established capability to fulfill federal medical procurement requirements through open competition and its significance as a key distributor of brand-name pharmaceuticals within the Department of Defense healthcare ecosystem.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $46.2k | 7/30/25 |